AMLOGENYX Trademark

Trademark Overview


On Wednesday, September 11, 2024, a trademark application was filed for AMLOGENYX with the United States Patent and Trademark Office. The USPTO has given the AMLOGENYX trademark a serial number of 98745183. The federal status of this trademark filing is RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Friday, March 28, 2025. This trademark is owned by Amlogenyx Inc.. The AMLOGENYX trademark is filed in the Chemical Products and Pharmaceutical Products categories with the following description:

Chemical, biological, and biochemical preparations for use in gene delivery technology, namely, nucleic acids in the nature of coding and non-coding deoxyribonucleic acids, plasmids, vectors, promotors, enhancers and regulatory sequences, for medical purposes for use in vitro laboratory use

Chemical, biological, and biochemical preparations for use in gene delivery technology, namely, nucleic acids in the nature of coding and non-coding deoxyribonucleic acids, plasmids, vectors, promotors, enhancers and regulatory sequences, for scientific purposes for use in vitro laboratory use; chemical, biological, and biochemical preparations for use in the manufacture of pharmaceutical preparations
amlogenyx

General Information


Serial Number98745183
Word MarkAMLOGENYX
Filing DateWednesday, September 11, 2024
Status661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED
Status DateFriday, March 28, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesChemical, biological, and biochemical preparations for use in gene delivery technology, namely, nucleic acids in the nature of coding and non-coding deoxyribonucleic acids, plasmids, vectors, promotors, enhancers and regulatory sequences, for medical purposes for use in vitro laboratory use
Goods and ServicesChemical, biological, and biochemical preparations for use in gene delivery technology, namely, nucleic acids in the nature of coding and non-coding deoxyribonucleic acids, plasmids, vectors, promotors, enhancers and regulatory sequences, for scientific purposes for use in vitro laboratory use; chemical, biological, and biochemical preparations for use in the manufacture of pharmaceutical preparations

Classification Information


International Class001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
US Class Codes001, 005, 006, 010, 026, 046
Class Status Code6 - Active
Class Status DateWednesday, September 11, 2024
Primary Code001
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, March 28, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAmlogenyx Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNovato, CA 94949

Trademark Events


Event DateEvent Description
Wednesday, September 11, 2024NEW APPLICATION ENTERED
Friday, January 24, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, March 12, 2025ASSIGNED TO EXAMINER
Friday, March 14, 2025NON-FINAL ACTION E-MAILED
Friday, March 14, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, March 28, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, March 28, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, March 28, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, March 14, 2025NON-FINAL ACTION WRITTEN